BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry

Terminated

Conditions: Hemophilia A

Interventions: Drug: New FVIII products

First Posted Date: 2018-07-27

Last Posted Date: 2022-08-25

Lead Sponsor: Bayer

Target Recruit Count: 3

Registration Number: NCT03603275

Locations: 🇺🇸
Emory / Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸
Boston Hemophilia Center at Children's Hospital of Boston/Brigham Women's, Boston, Massachusetts, United States
🇺🇸
Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States

and more 24 locations

Study on the Safety of the Approved Product Empedic L Cream During Its Routine Use (Active Ingredient is Clotrimazole 1%)

Completed

Conditions: Vaginal Candida

Interventions: Drug: Clotrimazole 1% (Empecid L Cream, BAYB5097)

First Posted Date: 2018-07-26

Last Posted Date: 2022-07-22

Lead Sponsor: Bayer

Target Recruit Count: 1033

Registration Number: NCT03599323

Locations: 🇯🇵
Many Locations, Multiple Locations, Japan

Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose

Phase 4

Completed

Conditions: Magnetic Resonance Imaging

Interventions: Drug: Gadoterate (Dotarem/Clariscan)
Drug: Gadobutrol (Gadavist/Gadovist, BAY86-4875)

First Posted Date: 2018-07-26

Last Posted Date: 2021-06-14

Lead Sponsor: Bayer

Target Recruit Count: 157

Registration Number: NCT03602339

Locations: 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇬🇧
Royal Preston Hospital, Preston, Lancashire, United Kingdom
🇩🇪
Friedrich-Schiller-Uni. Jena, Jena, Thüringen, Germany

and more 17 locations

Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors

Phase 2

Terminated

Conditions: Hemophilia A and B

Interventions: Drug: Befovacimab (BAY1093884)

First Posted Date: 2018-07-24

Last Posted Date: 2020-11-30

Lead Sponsor: Bayer

Target Recruit Count: 24

Registration Number: NCT03597022

Locations: 🇦🇺
Fiona Stanley Hospital, Murdoch, Western Australia, Australia
🇫🇷
Hôpital Robert Debré - Reims Cedex, Reims Cedex, France
🇫🇷
Hôpital Louis Pradel - Bron, Bron, France

and more 14 locations

A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms

Phase 2

Completed

Conditions: Hot Flashes
Menopause
Night Waking

Interventions: Drug: Elinzanetant (BAY3427080)
Drug: Placebo

First Posted Date: 2018-07-24

Last Posted Date: 2023-03-10

Lead Sponsor: Bayer

Target Recruit Count: 199

Registration Number: NCT03596762

Locations: 🇺🇸
Study Site 13, Aventura, Florida, United States
🇺🇸
Study Site 15, Lake Worth, Florida, United States
🇨🇦
Study Site 50, Red Deer, Alberta, Canada

and more 22 locations

Study of BAY1834942 in Patients With Solid Tumors

Phase 1

Completed

Conditions: Advanced CEACAM6-expressing Solid Tumors

Interventions: Drug: BAY1834942

First Posted Date: 2018-07-23

Last Posted Date: 2022-06-02

Lead Sponsor: Bayer

Target Recruit Count: 30

Registration Number: NCT03596372

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇨🇦
Princess Margaret Hospital-University Health Network, Toronto, Ontario, Canada

and more 1 locations

Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"

Phase 1

Active, not recruiting

Conditions: Hemophilia A

Interventions: Drug: BAY2599023 (DTX201)

First Posted Date: 2018-07-17

Last Posted Date: 2024-12-16

Lead Sponsor: Bayer

Target Recruit Count: 11

Registration Number: NCT03588299

Locations: 🇧🇬
SHATHD Spec. Hospi. for Active Treatm. of Haematol. Dis. EAD, Sofia, Bulgaria
🇺🇸
University of Wisconsin - Madison, Madison, Wisconsin, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States

and more 10 locations

EffectiveNess of Low Dose Aspirin in GastrointEstinal Cancer Prevention - Taiwan

Completed

Conditions: Colorectal Neoplasms

Interventions: Other: No drug
Drug: Aspirin (Acetylsalicylic Acid, BAYE4465)

First Posted Date: 2018-07-09

Last Posted Date: 2020-09-29

Lead Sponsor: Bayer

Target Recruit Count: 4710504

Registration Number: NCT03579732

Locations: 🇨🇳
National University of Taiwan Hospital, Taipeh, Taiwan

Betaferon Use in Children and Adolescents With Multiple Sclerosis

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Interferon beta-1b (Betaseron, Betaferon, BAY86-5046)

First Posted Date: 2018-07-05

Last Posted Date: 2018-07-11

Lead Sponsor: Bayer

Target Recruit Count: 70

Registration Number: NCT03577977

Assess Safety and Efficacy of Vilaprisan in Subjects With Endometriosis

Phase 2

Terminated

Conditions: Endometriosis

Interventions: Drug: Vilaprisan (BAY1002670)
Drug: Matching Placebo

First Posted Date: 2018-06-29

Last Posted Date: 2022-05-04

Lead Sponsor: Bayer

Target Recruit Count: 8

Registration Number: NCT03573336

Locations: 🇦🇹
Medizinische Universität Graz, Graz, Steiermark, Austria
🇦🇹
KABEG Landeskrankenhaus Villach, Villach, Austria
🇺🇸
Unified Women's Clinical Research, Winston-Salem, North Carolina, United States

and more 20 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy